We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Spectrum Pharmaceuticals Initiates Phase 1 Study of a Novel Adjunct to Cancer Chemotherapy
News

Spectrum Pharmaceuticals Initiates Phase 1 Study of a Novel Adjunct to Cancer Chemotherapy

Spectrum Pharmaceuticals Initiates Phase 1 Study of a Novel Adjunct to Cancer Chemotherapy
News

Spectrum Pharmaceuticals Initiates Phase 1 Study of a Novel Adjunct to Cancer Chemotherapy

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Spectrum Pharmaceuticals Initiates Phase 1 Study of a Novel Adjunct to Cancer Chemotherapy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Spectrum Pharmaceuticals, Inc. has announced that the first patient has received SPI-1620 in a Phase 1 dose-escalation study. SPI-1620, a highly selective endothelin-B agonist, is being developed as an adjunct to cancer chemotherapy.

The Phase 1 trial is an open label, dose-escalation study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of SPI-1620 in patients with recurrent or progressive carcinoma.

“In preclinical studies, administering SPI-1620 fifteen minutes prior to chemotherapy demonstrated up to 400% increase in drug concentration in the tumors, resulting in increased tumor response,” said Rajesh C. Shrotriya, M.D., President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc.

“We believe that with further clinical development, SPI-1620 has the potential to significantly increase the efficacy of a broad range of chemotherapeutic drugs used for the treatment of solid tumors,” Shrotriya added.

Advertisement